China Biologic Products Holdings, Inc. (CBPO): Price and Financial Metrics

China Biologic Products Holdings, Inc. (CBPO)

Today's Latest Price: $108.78 USD

0.08 (0.07%)

Updated Mar 30 12:51pm

Add CBPO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 117 in China

See all "A" rated Strong Buy stocks

CBPO Stock Summary

  • The ratio of debt to operating expenses for China Biologic Products Holdings Inc is higher than it is for about only 0.34% of US stocks.
  • CBPO's price/sales ratio is 8.28; that's higher than the P/S ratio of 90.06% of US stocks.
  • The volatility of China Biologic Products Holdings Inc's share price is greater than that of merely 9.8% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to China Biologic Products Holdings Inc are IMAX, ROLL, TTGT, TC, and MICT.
  • Visit CBPO's SEC page to see the company's official filings. To visit the company's web site, go to
CBPO Daily Price Range
CBPO 52-Week Price Range

CBPO Stock Price Chart More Charts

CBPO Price/Volume Stats

Current price $108.78 52-week high $119.44
Prev. close $108.70 52-week low $88.00
Day low $107.96 Volume 24,249
Day high $109.95 Avg. volume 110,004
50-day MA $114.61 Dividend yield N/A
200-day MA $109.14 Market Cap 4.28B

China Biologic Products Holdings, Inc. (CBPO) Company Bio

China Biologic Products engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in China. The company is based in Beijing, the China.

CBPO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for China Biologic Products Holdings Inc. To summarize, we found that China Biologic Products Holdings Inc ranked in the 55th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 65.67% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for CBPO, they are:

  • The company's debt burden, as measured by earnings divided by interest payments, is 300.33; that's higher than 97.53% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than merely 0% of the free cash flow producing stocks we're observing.
  • CBPO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 63.89% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

AMED, SNY, FTLF, LH, and TVTY can be thought of as valuation peers to CBPO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

CBPO Latest News Stream

Event/TimeNews Detail
Loading, please wait...

CBPO Latest Social Stream

Loading social stream, please wait...

View Full CBPO Social Stream

CBPO Price Returns

1-mo -5.71%
3-mo -6.53%
6-mo -5.37%
1-year 19.21%
3-year 8.64%
5-year 12.33%
YTD -6.53%
2019 53.31%
2018 -3.63%
2017 -26.74%
2016 -24.53%
2015 111.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9333 seconds.